Revista médica de Chile
-
Revista médica de Chile · Nov 2023
[High Frequency of Mesenteric Panniculitis in Non-Hodgkin Lymphoma and Prostate Cancer: Study in 1,500 Oncologic Patients Undergoing Staging].
Mesenteric panniculitis (MP) is an uncommon, benign, condition that involves the mesenteric root. It may be idiopathic, or be associated with an inflammatory or malignant neoplasm. ⋯ MP is more frequently associated with some malignant neoplasms, such as non-Hodgkin lymphoma and prostate cancer, and rare in others. This must be considered when studying patients with MP detected incidentally.
-
Revista médica de Chile · Nov 2023
[Risk Factors for Cognitive Decline Among Elderly Chilean Adults: Insights from a National Study].
With a growing elderly population in Chile, the prevalence of neurocognitive disorders has increased, including dementia and its precursor, mild cognitive impairment. Identifying risk factors associated with cognitive impairment is critical in prevention. ⋯ Age, depression, visual impairment, and low activity are risk factors for cognitive impairment. Early identification of these conditions will allow the prevention of cognitive impairment.
-
Revista médica de Chile · Oct 2023
Review[Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis].
Siponimod is a selective immunosuppressive medication, developed as the first oral therapy for active secondary progressive multiple sclerosis. This medication acts by modulating the sphingosine 1 phosphate (S1P) receptor, as an antagonist of S1P1 and S1P5, thus preventing the egress of lymphocytes from lymph nodes and preventing inflammatory processes in the Central Nervous System that trigger demyelination. There is extensive scientific knowledge regarding the administration of the medication to patients, which will depend on their pharmacogenetic characteristics. ⋯ Additionally, before prescribing it, an electrocardiogram, assessments of antibody status, ophthalmic evaluation, varicella vaccination status, and peripheral lymphocyte count should be conducted, as the medication's effect is dose-dependent. Therefore, a titration process is carried out starting from 0.25mg up to 2 mg. The pharmacotherapeutic protocol of siponimod is a reliable reflection of the utility of pharmacogenetics in personalized medicine.